Registration is now open for the webinars on IMI2 – Call 13, which will be held on 27 November to 15 December. There will be webinars on all Call topics, as well as a webinar on IMI’s rules and procedures. In addition, there will be a dedicated webinar for small and medium-sized enterprises (SMEs), to highlight the opportunities for them in this Call and provide them with information that may be particularly relevant for them.
Although IMI2 - Call 13 has not yet been launched, the indicative topic texts are available on the Future Topics page.
Registration is free but obligatory via the links on the webinar web page. When you register, you will receive an automatic confirmation e-mail with your own personal web link and dial-in number which you should use on the day. All times given are Brussels time (Central European Time, CET).
7/12, 15:00: IMI rules & procedures
7/12, 10:00: Opportunities for SMEs in IMI2 – Call 13
27/11, 15:00: Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
1/12, 10:30: Human tumour microenvironment immunoprofiling
4/12, 10:30: Mitochondrial dysfunction in neurodegeneration
4/12, 15:00: Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
5/12, 10:30: Federated and privacy-preserving machine learning in support of drug discovery
6/12, 10:30: Pilot programme on a clinical compound bank for repurposing (includes the following topics: cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; rare/orphan diseases)
11/12, 10:30: A sustainable European induced pluripotent stem cell platform
11/12, 15:00: CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
12/12, 15:00: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
14/12, 10:30: Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
14/12, 15:00: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
15/12, 10:30: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
15/12, 15:00: Genome-environment interactions in inflammatory skin disease